66 results about "Active immunity" patented technology

The invention relates to compositions of a deacetylated poly N-acetylated glucosamine (dPNAG) of Staphylococci. The dPNAG may be isolated from natural sources or synthesized de novo. The invention also relates to the use of dPNAG as a vaccine for inducing active immunity to infections caused by Staphylococcus aureus, S. epidermidis, other related coagulase-negative or coagulase-positive Staphylococci, and other organisms carrying the ica (intracellular adhesion) locus. The invention further provides methods of use for antibodies directed to dPNAG, particularly for inducing passive immunity to the same class of infections.

The invention relates to an infant nutrition immunity formula powdered milk and a production method thereof, wherein, the production method of the infant nutrition immunity formula powdered milk comprises the following steps: milk which is raw material, is preprocessed, the mixed solution of docosahexaenoic acid and arachidonic acid is prepared, ingredients are mixed, preheating, homogenizing and heating are carried out for sterilizing, decompression is carried out for concentrating, and spray-drying under negative pressure and low temperature and drying on a fluidized bed are carried out, then cooling, packing and inspecting are carried out. The infant nutrition immunity formula powdered milk manufactured by the method of the invention mainly comprises casein phosphoeptide, vitamin D3, lactoferrin, nucleotide, linoleic acid, linolenic acid, the docosahexaenoic acid, the arachidonic acid, fructo-oligosaccharide and galacto-oligosaccharide, which has the advantage of reasonable trophic structure and also ensures that various nutrient substance to be absorbed and deposited to the utmost extend, so as to promote the development of brain and nervous system, improve active immunity, improve intestinal tract micro-ecological environment and strengthen the absorption of calcium, iron and zinc as well as effectively maintain every active nutrient component during the production process.

Carbon nanotube (CNT)-based compositions for activating cellular immune responses are provided. The CNTs function as high surface area scaffolds for the attachment of T cell ligands and / or antigens. The CNT compositions function as artificial antigen-presenting cells (aAPCs) or as modular vaccines. The disclosed CNT aAPCs are efficient at activating T cells and may be used to activate T cells ex vivo or in vivo for adoptive or active immunotherapy.

A number of immunologically active agents are described, including an isolated protein or polypeptide that includes the amino acid sequence of SEQ ID NO: 1, immunogenic conjugates containing either the protein or polypeptide, a full-length Pneumocystis kexin, or a full length Streptococcus pneumoniae pneumococcal surface protein A (PspA), antibodies recognizing the protein or polypeptide or the immunogenic conjugates (particularly the epitope of SEQ ID NO: 1), and nucleic acid molecules that encode the protein or polypeptide, as well as DNA constructs, expression vectors, and host cells that contain the nucleic acid molecules. Disclosed uses of the antibodies, immunogenic conjugates, and DNA constructs include inducing passive or active immunity to treat or prevent pathogen infections, particularly by a Pneumocystis organism, in a patient.

The invention discloses a preparation method and application of Newcastle disease virus infected immune complex vaccines. The preparation method comprises the following steps of: (1) preparing antigens and inactivated vaccines by using Newcastle disease virus Shanghai strains as seed viruses; (2) transferring antibodies in chicken blood serum to yolk to form yolk antibodies IgY; and (3) mixing the prepared inactivated vaccines and the yolk antibodies IgY in equal volume, and hatching to obtain the immune complex vaccines. By combining passive immune (vaccine) and active immune (specific antibody) measures, animals are protected from the infection of pathogenic microbes in time for a long time.

The present invention provides vaccines and methods for making the vaccines that actively or passively protect an equid or other animal against Sarcocystis neurona. In particular, the present invention provides vaccines that provide active immunity which comprise a polypeptide or DNA vaccine that contains or expresses at least one epitope of an antigen that has an amino acid sequence substantially similar to a unique 16 (±4) kDa antigen and / or 30 (±4) kDa antigen of Sarcocystis neurona. The present invention further provides a vaccine that provides passive immunity to Sarcocystis neurona comprising polyclonal or monoclonal antibodies against at least one epitope of an antigen substantially similar to a unique 16 (±4) kDa antigen and / or 30 (±4) kDa antigen of Sarcocystis neurona.

The invention discloses a power terminal and an information safety protection method and system of an embedded system of the power terminal, information safety protection is actively carried out through immune self-stabilization, immune monitoring and immune defense modes according to an artificial immune principle, and the method comprises the following steps: S1, establishing an embedded systemendogenous credible operation environment for immune self-stabilization; S2, loading an embedded system abnormality detection logic inspection program for immunomonitoring; S3, selecting whether to load a fault emergency processing and event recording program for immune defense or not according to the result checked in the step S2: if the result checked in the step S2 is abnormal, loading the fault emergency processing and event recording program for immune defense; otherwise, not loading. According to the invention, three major functions of immune self-stabilization, immune monitoring and immune defense of human immunity are simulated, the power terminal is endowed with an anthropomorphic active immune safety protection capability, the information safety of the power industrial control terminal is maintained to a certain extent, and the safety risk of the power terminal is reduced.

The invention discloses a broad-spectrum anti-tumor double-plasmid reproducible DNA vaccine. Active ingredients of the broad-spectrum anti-tumor double-plasmid reproducible DNA vaccine comprise a tumor antigen compound gene-carrying anti-tumor antigen replicon DNA vaccine pSVK-CACA and a tumor blood vessel compound gene-carrying anti-tumor blood vessel replicon DNA vaccine pSVK-CAVE, wherein the tumor antigen compound gene-carrying anti-tumor antigen replicon DNA vaccine pSVK-CACA and the tumor blood vessel compound gene-carrying anti-tumor blood vessel replicon DNA vaccine pSVK-CAVE are constructed by using a replicon DNA vaccine carrier pSVK as a starting carrier. The broad-spectrum anti-tumor double-plasmid reproducible DNA vaccine provides a new choice for anti-tumor active immunity treatment and has a broad application prospect.

The invention belongs to the medical technical field and discloses a method for preparing a ligand-mediated dendritic cell targeting nanometer agent serving as a tumor vaccine carrier. According to the method, tumor antigen peptide or a compound formed by tumor antigen peptide and heat shock protein is entrapped in the ligand-modified nanometer agent, the ligand is an antibody capable of being specifically bound with a dendritic cell surface receptor, so that a dendritic cell is specifically targeted, antigenic information is presented onto the surface of the cell through ingestion, processing and treatment of the nanometer agent by means of the dendritic cell, and then recognition of tumor antigen information is achieved by specific cytotoxic T lymphocyte, active immunity of an organism is achieved, tumor cells are killed, and tumor is treated. According to the nanometer agent tumor vaccine preparing method, design is reasonable, preparation is easy, and application prospect is broad.

The invention provides an active immune attack identification method. The active immune attack identification method comprises the following steps: acquiring a real-time data stream of a charging device; carrying out real-time detection and classification on the data flow through a stack type self-encoding network model so as to judge whether abnormal data exists in the data flow or not, and directly forwarding the data when the abnormal data does not exist; and when abnormal data exists, intercepting the real-time data flow, sending out an alarm prompt, generating a log record, and meanwhile,stopping the machine. The invention further provides a charging device. Compared with the prior art, the data obtained by the charging device is analyzed and classified through the stack type auto-encoder network model, and the probability of being attacked by the network is output, so that whether the data is attacked or not is judged, corresponding operation is executed, the information safetyand the operation reliability of the charging device are guaranteed, and the safety of a power grid is guaranteed.

The present invention provides a method for producing a vaccine against cancerous disease, and the vaccine itself. This method involves first using one or more antibodies that are specifically effective against one or more antigens specially expressed by the tumor cells to select one or more mimotopes of said antigens from a phage peptide library. To obtain the vaccine, said mimotopes are conjugated to a macromolecular carrier singly or multiply in the form of their mono-, di-, tri- or oligomers. When administered, the inventively produced vaccine leads to a humoral immune response and thus to the formation of an active immunity as a consequence of vaccination.

The present invention discloses a simulation epitope of 12 amino acids of human cell B specificity expression membrane molecule CD 20 and its polypeptide epitope vaccine constructed by using said simulation spitope. Said invention also provides a method for screening simulation epitope of CD 20 molecule by using Rituximab as ligand, and provides its amino acid sequence, Gln-Asp-Lys-Leu-Th-Gln-Try-Pro-Lys-Try-Leu-Glu. Said invention also provides a method for chemically-synthesizing simulation epitope of 12 amino acids and making it be chemically-coupled with keyhole limpet hemo cyanin (KLH) to obtain the successfully-constructed vaccine. Besides, said invention also provides the concrete application of said vaccine.

The invention provides a preparation method of a tumor fusion cell vaccine. The preparation method comprises the following steps of fusing genes of an alpha-TCR (T cell receptor) and a beta-TCR into an alpha and beta-TCR; obtaining a recombinant plasmid; constructing the alpha and beta-TCR into a shuttle plasmid pMP71-alpha and beta-TCR; transfecting gamma-delta T cell by the gene of alpha and beta-TCR; using an electric fusion technique to fuse the gamma-delta T cell and tumor cell into a vaccine. The preparation method has the advantages that the fusion cell is formed by the gamma-delta T cell transfected by the gene of alpha and beta-TCR and the tumor cell, so as to prepare the vaccine; the specificity of tumor cell can be identified, the capability of the fusion cell inducing the withering of the tumor cell is strongest, and the active immunity of the body receptor is stimulated to treat tumors.

The invention provides a CXCL13 (chemokine(C-X-C motif) ligand 13) DNA vaccine and an application thereof. According to the CXCL13 DNA vaccine, overall-length cDNA of CXCL13 and HBc (Hepatitis B core) are connected, and a vector is pcDNA 3.1(-). A tumor targeted drug prepared from the CXCL13 DNA vaccine generates stronger humoral immunity response by stimulating an active immunity system of an organism and can inhibit p-AKT, p-ERK and EMT signal pathways, thereby inhibiting tumor cell growth as well as invasion and metastasis and realizing the anti-tumor effect.

The invention provides a trusted cloud platform measurement system and method. The system comprises at least one virtual trusted root front end driving module for acquiring an application request andsending the application request to a virtual trusted root back end driving module, wherein the virtual trusted root back end driving module is used for adding a label corresponding to each virtual machine, and generating an identification application request and sending to a physical trusted root driving module; a life cycle management module for generating a measurement instruction according to astarting behavior of each virtual machine and system environment of a host machine, and sending the measurement instruction to the physical trusted root driving module to execute through the virtualtrusted root management module; the physical trusted root driving module for performing trusted measurement test on the label application request to generate a measurement result, and sending the result to the physical trusted root module so that the physical trusted root module determines whether the host machine executes the application request according to the measurement result. By implementing the measurement system disclosed by the embodiment, the security of the cloud platform body is reinforced, the active immunity mechanism on malicious attack by the cloud platform is realized, and the solid foundation is laid for constructing the safe and trusted electric cloud platform.

The present invention provides an active immune regulation particle. The active immune regulation particle comprises a microcarrier, the microcarrier is loaded with at least SYNZIP1 polypeptide, SYNZIP2 polypeptide, nucleic acid molecule CpG, a T cell promoter, an antibody Fc segment and an antigen, an amino acid sequence of the SYNZIP1 polypeptide is shown in SEQ ID NO:1 and an amino acid sequence of the SYNZIP2 polypeptide is shown in SEQ ID NO:2. The active immune regulation particle can overcome immune suppression environment of tumor microenvironment, breaks immune tolerance, improves immune response of the entire immune system to tumor antigens, quickly and efficiently activate immune responses of tumor-specific B cells and T cells to kill tumors, and can also promote proliferation of the immune cells through stimulation by cytokines. Through administration by subcutaneous injection, the active immune regulation particle can be passively targeted into tumor tissues through capillaries and quickly endocytosed by the immune cells and tumor cells.

The invention provides a vaccine based on an epitope simulating human vascular endothelial growth factor VEGF, as well as a preparation method thereof. A VEGF mimic epitope which is specifically affinitive with human-mouse chimeric monoclonal antibody Avastin is screened out by use of a phage random presentation technique, and the amino acid sequence of the mimic epitope is Asp-His-Thr-Leu-Tyr-Thr-Pro-Tyr-His-Thr-His-Pro; the mimic epitope has no homology with the protein sequence of VEGF. A vaccine which can induce a polypeptide epitope aiming at VEGF molecular autoantibody in vivo is constructed on the basis of the mimic epitope. The invention provides a strategy for developing and designing the tumor therapeutic vaccine, which is targeted at the VEGF. The VEGF is one of molecules which has the strongest effect of promoting vascular growth, and is an ideal target for resisting angiogenesis and treating tumors. Therefore, the vaccine replaces or replenishes monoclonal antibody passive immunotherapy with an active immunity mode, so as to lay foundations for overcoming the defects of monoclonal antibody therapy.

The invention belongs to the preparation field of vaccine for animals. It adopts the gene engineering method, clones the gene of muscle somatostatin and expresses the recombined confluence protein of the muscle somatostatin in Escherichia coli or yeast as an immunogen or gene engineering vaccine. Active immunity for growing livestock and birds by the muscle somatostatin engeneering vaccine can promote the animal to generate antibody of the muscle somatostatin, which can neutralize and inhibit the muscle somatostatin produced by self muscle of the livestock and birds, thus absolves the muscle growth inhibiting function of the muscle somatostatin and promotes the muscle growth.

Chimeric double peptide vaccines are disclosed, useful for inducing active immunity against Candida fungal infections. The chimeric peptide comprises an Fba peptide and an Met6 peptide, covalently linked to one another, with or without an intermediate linker. Fba and Met6 are cell surface components of Candida. When used as a vaccine, the chimeric double peptide vaccine induces stronger protective immunity against fungal infection than does the Fba peptide alone, or the Met6 peptide alone, or a mixture (not covalently linked) of the two peptides.

The invention discloses a reticulitermes chinensis Snyder SeBP gene and application of combination of dsRNA of the Reticulitermes chinensis Snyder SeBP gene and metarhizium anisopliae in termite control. The nucleotide sequence of the reticulitermes chinensis Snyder SeBP gene is as shown in SEQ ID No.1, and the dsRNA of the reticulitermes chinensis Snyder SeBP gene is designed based on the same. The dsRNA is injected into bodies of the termites; sterile termites injected with the dsRNA actively contact uninjected termites directly infected with metarhizium anisopliae, and then the uninjected termites obtaining a small amount of metarhizium anisopliae spores become infected companion termites; and after a specified observation time, the antibacterial activity and the survival rate of the infected companion termites are obviously reduced, which indicates that the active immunity of the infected companion termites is broken, and the injection of dsSeBP obviously improves the control effect of the metarhizium anisopliae on the termites. The obtained SeBP gene can be used as a molecular target for termite control, and is combined with metarhizium anisopliae for use, which effectively improves the termite control effect, and has a good application prospect.

The invention discloses an immunogen and antibody composite vaccine and a preparation method thereof. The composite vaccine consists of an immunogen at the center, an oil phase for coating the immunogen at the middle, and an antibody for coating the oil phase at the outer part, therefore, a water-in-oil-in-water (W / O / W) type emulsion system is formed. Within several hours after the composite vaccine is injected, the antibody is firstly and quickly released in the early stage, and then is absorbed by an organ and enters blood for immunization; the immunogen is then released, and is induced to generate effective active immunity within 4 to 6 days before the antibody loses the immunity. The composite vaccine has the advantage that seamless connection between specific passive immunity and specific active immunity is realized, adding complementation is achieved, and an effect can be taken quickly.

An injection for improving active immunity is a trace element one prepared from water-soluble compounds including sodium selenite, cobalt sulfate, copper sulfate, zinc gluconate, iron citrate, manganese sulfate, magnesium sulfate, sodium chromate, and sodium vanadate. Its advantages are low dosage and no toxic by-effect.

The invention relates to preparation method of prostatic cancer specific DC cell vaccine which is insensitive to TGF-belta, which can treat prostatic cancer effectively, and is prostatic cancer specific immunization gene treatment with genuine with truly implemented combination of active immunity and adoptive cellular immunity. The technical scheme of the present invention applied is: 1) constructing retrovirus containing dominant negative TGF-belta II type (T belta RIIDN) plasmid; 2) separating, culturing and identifying DC cells loaded with prostatic cancer antigen; 3) transfection of DC cells to obtain T belta RIIDN-DC cells; 4) vitro experiments of the T belta RIIDN-DC cells; 5) antitumor estimate of the DC vaccine in vivo; 6) CTL activity detection in vivo.

Methods of treating eosinophilia by down regulating eotaxin and at least one other Th-2 related cytokine are dislosed as are multivalent immunogenic compositions that generate an active immune response in a subjet comprising autoantibodies to eotaxin-1, eotaxin-2, IL-4, IL-5, IL-9, and IL-13 and treatment methods using such compositions.

The invention discloses a static measurement method of an active immune trusted computing platform for a blockchain master node, the trusted computing platform comprises a computing component and a protection component which are parallel, the computing component is used for completing computing tasks such as blockchain consensus, blockchain communication and blockchain transaction, and the protection component is used for performing active measurement and active control on the computing component according to the dynamic autonomous credible strategy through an active immune chip; the static measurement method comprises the steps that after a trusted computing platform is powered on, an active immune chip in a protection component is started before a block chain special CPU and hardware ina computing component, the protection component measures the starting process of the computing component step by step through an active immune chip agent with the active immune chip as the root of trust until the trust chain of the computing component is established. According to the method, the active immune chip serves as a source point of active measurement and active control, a safe and credible trust chain is constructed for the computing component, and the safety performance of the computing component can be effectively guaranteed.

The invention discloses an active immunoregulation method for fused prolactin proteins of goose eggs, which comprises the simple steps of extraction, enzyme digestion, induction, purification, concentration, mixing and injection. The active immunoregulation method has the advantages that recombinant expression fused prolactin proteins are applied to active immunity of gooses, and the reproductive performance of the gooses is improved through regulating the body's hormone level, so that the difficult problem that in the conventional breeding, broody traits are difficult to eliminate is solved, and meanwhile, the problem that drug residue caused by injecting sex hormone substances by people is also avoided.

Immunologically active agents are described, including isolated Pneumocystis A 12 protein or polypeptides; immunogenic conjugates containing Pneumocystis A 12 protein or polypeptide of the present invention; antibodies recognizing the Pneumocystis A 12 protein or polypeptide or the immunogenic conjugates of the present invention; and nucleic acid molecules that encode the Pneumocystis A 12 protein or polypeptide of the present invention, as well as DNA constructs, expression vectors, and host cells that contain the nucleic acid molecules. Disclosed uses of the antibodies, immunogenic conjugates, and DNA constructs include inducing passive or active immunity to treat or prevent pathogen infections, particularly by a Pneumocystis organism, in a subject.

The invention belongs to the field of animal feeds, and particularly discloses a feed additive capable of enhancing the immunity of rabbits and a preparation method of the feed additive. According to the feed additive capable of enhancing the immunity of the rabbits and the preparation method of the feed additive disclosed by the invention, the feed additive is prepared from the following active components of radix cynanchi atrati, mint, poria cocos, golden buckwheat rhizomes, rice beans, pittosporum illicioides, common sowthistle herbs, aralia elata, dioscorea subcalva prain et burhll, shiitake mushrooms, luffa vegetable sponges, fortune eupatorium herbs, atractylodes lancea, eucalyptus citriodora leaves, white mulberry root bark, millettia specisoa roots, garlic powder and ficus simplicissima in certain parts by weight. The preparation method of the feed additive capable of enhancing the immunity of the rabbits disclosed by the invention is simple, all the raw materials have complementary advantages, and the mutual synergistic or resistant effects of the raw materials are utilized, so that the appetite of the rabbits is fundamentally stimulated, the constitutions of the rabbits are strengthened, and the disease resistance of the rabbits is improved; the use of antibiotics is reduced, so that the quality of rabbit meat is improved, besides, various special bioactive substances can be provided, the establishment of an active immunity system of the rabbits is stimulated, and the disease prevention and disease resistance of the rabbits are strengthened, so that the appetite of the rabbits is good, the excrement of the rabbits is moist, the skin of the rabbits is red, the hair of the rabbits is bright, and the economic utilization value is increased.